Global Carcinoid Syndrome Management Market size is expected to increase USD 500 Million by the end of 2022.

Pune, India, May, 2017 /MRFR Press Release/- Market research future has a half cooked research report on global carcinoid syndrome management market. The global Carcinoid Syndrome Management market is growing at an average rate and is expected to grow further its growth by the end of 2022.

Market Highlights

The global Carcinoid Syndrome Management market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. The global market for carcinoid syndrome management is highly consolidated and very rare number of players constitute the entire market. Chemotherapy treatment type segment is expected to dominate the global market for carcinoid syndrome management over the forecast period as chemotherapy is used as a first line treatment. Newly introduced hepatic artery embolization agents are anticipated to gain the significant share in the global market over the forecasted period. The market is expected to grow at an average CAGR due to growing awareness towards the symptoms of carcinoid tumor among the general population. The primary factor driving the growth of global carcinoid syndrome market is incidence of carcinoid tumor. As per National Institute of Health statistics, worldwide rate of carcinoid tumor is 2 per 100,000 person with high incidence of GI carcinoid tumors. Every year over 8,000 patients in the U.S are identified with carcinoid tumor in GI tract. Other factors influencing the global carcinoid syndrome management market include increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. Factor restraining the growth of global carcinoid syndrome management market is no availability of drugs approved to manage carcinoid syndrome.

Asia Pacific is expected to be the fastest growing market and is expected to continue to grow at the same rate during the forecasted period. North America with the largest market share of 70% in 2013 of the global Carcinoid Syndrome Management   market due to high prevalence of diseases, and easy availability of Carcinoid Syndrome Management treatment facilities due to widespread healthcare infrastructure and government encouragement to medical innovation and is expected to grow further during the forecasted period. Developing countries were reported to have maximum cases of the disease but due to lack of technology advancement and healthcare facilities and also because of high cost of treatment and check-up and lack of awareness, only few cases were reported and treated in the last 7 years.

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Carcinoid Syndrome Management market Research Report –Global Forecast to 2022.

Access Report Details @ https://www.marketresearchfuture.com/reports/carcinoid-syndrome-management-market-2843

Global Carcinoid Syndrome Management market Players:

The major participants of this market are: Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and  Sun Pharmaceutical Industries Limited (India),

Segmentation:

The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Small intestine are the most likely to get affected by the disease and maximum cases reported were of the small intestine only. Other organs constitute rare chances of getting affected. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.

Figure 1           Global Carcinoid Syndrome Management Market by Treatment type

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact US

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com